Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEUROMUSCULAR DISEASE

Getting specific: targeting Fc receptors in myasthenia gravis

Nature Reviews Neurology volume 17, pages 597–598 (2021)Cite this article

Subjects

A randomized, placebo-controlled trial has found the neonatal Fc receptor modulator efgartigimod to be an effective therapy for generalized myasthenia gravis. If a pending FDA application is approved, the treatment will be the first recombinant antibody-based therapy for selective IgG depletion, adding to a growing spectrum of treatment options for myasthenia gravis.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Efgartigimod and Abdegs harness neonatal Fc receptor function.

References

  1. Toyka, K. V. et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296, 125–131 (1977).

    Article  CAS  Google Scholar 

  2. Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Primers 5, 30 (2019).

    Article  Google Scholar 

  3. Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nat. Rev Neurol. 15, 113–124 (2019).

    Article  Google Scholar 

  4. Howard, J. F. Jr et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526–536 (2021).

    Article  Google Scholar 

  5. argenx. argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis. argenx https://www.argenx.com/news/argenx-announces-fda-acceptance-bla-filing-efgartigimod-treatment-generalized-myasthenia (2021).

  6. Kiessling, P. et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci. Transl Med. 9, eaan1208 (2017).

    Article  Google Scholar 

  7. Ulrichts, P. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. 128, 4372–4386 (2018).

    Article  Google Scholar 

  8. Lunemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80–89 (2015).

    Article  CAS  Google Scholar 

  9. Vollmer, B. L. et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann. Clin. Transl Neurol. 7, 1477–1487 (2020).

    Article  CAS  Google Scholar 

  10. Howard, J. F. Jr et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92, e2661–e2673 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany

    Jan D. Lünemann

Authors
  1. Jan D. Lünemann
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jan D. Lünemann.

Ethics declarations

Competing interests

J.D.L. has received speaker fees, research support, and/or served on advisory boards at the Swiss National Science Foundation, the German Research Foundation, the Swiss Multiple Sclerosis Society, AbbVie, Alexion, ArgenX, Bayer AG, Biogen Inc, F. Hoffmann-La Roche, Merck & Co., Novartis AG and Sanofi Genzyme.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lünemann, J.D. Getting specific: targeting Fc receptors in myasthenia gravis. Nat Rev Neurol 17, 597–598 (2021). https://doi.org/10.1038/s41582-021-00547-z

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41582-021-00547-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing